Cisplatin Toxicity in Children with Malignancy

Antonio Ruggiero², Giovanna Trombatore², Silvia Triarico², Michele Antonio Capozza², Paola Coccia¹, Giorgio Attina², Stefano Mastrangelo² and Palma Maurizi²    

¹Pediatric Hemato-oncology Unit, Ospedale Salesi, Azienda Ospedali Riuniti Ancona, Ancona, Italy

²Pediatric Oncology Unit, Fondazione Policlinico Universitario A .Gemelli IRCCS, Universita’ Cattolica Sacro Cuore, Roma, Italy

Corresponding Author E-mail: antonio.ruggiero@unicatt.it

Abstract: Platinum’ derivates are antineoplastic agents widely adopted for their efficacy for the treatment of many pediatric cancers. The use of cisplatin has positively influenced the results of the cure of different childhood malignancies. However, cisplatin-based treatments are limited by the risk of severe and progressive toxicities, such as oto- or nephrotoxicity, that can be more serious in very young children expecially when high cumulative doses and/or radiotherapy is administered. A correct knowledge of the cisplatin’ pharmacological features might be of interest for clinicians in order to manage its potential toxicities. Based on the positive trend in the cure of children with cancer, it is crucial that all children receiving cisplatin-based chemotherapy have and appropriate and long-term follow-up to improve their quality of life.

Keywords: Cisplatin; Children; Nephrotoxicity; Neurotoxicity; Myelotoxicity; Ototoxicity

[ HTML Full Text]

Back to TOC